Literature DB >> 30638733

Evaluation of a diagnostic 18F-FDG PET/CT strategy for differentiating benign from malignant retroperitoneal soft-tissue masses.

C H Lim1, H Y Seok2, S H Hyun1, S H Moon1, Y S Cho1, K-H Lee1, B-T Kim1, J Y Choi3.   

Abstract

AIM: To investigate the optimal combined 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)/computed tomography (CT) diagnostic criteria for distinguishing between benign and malignant retroperitoneal soft-tissue masses (RPMs).
MATERIALS AND METHODS: A total of 74 patients (M:F=34:40; age, 53±13.2 years) who underwent FDG PET/CT for the initial work-up of RPMs were included. The maximum standardised uptake value (SUVmax), tumour size, presence of fat or calcifications and separated hypermetabolic lesions were included as PET/CT diagnostic parameters. Receiver-operating characteristic (ROC) curves were used to compare the diagnostic performance.
RESULTS: The final pathological diagnoses included 52 malignant and 22 benign tumours. High SUVmax (>4.8) and large size (>13 cm) favoured malignancy, and yielded a diagnostic accuracy and AUC of 64.9%, 0.820±0.059, and 68.9%, 0.738±0.061, respectively. In a subgroup of RPMs with a fat component, both SUVmax and size were significantly different between benign and malignant RPM, which yielded a diagnostic accuracy and AUC of 91%, 0.977±0.024 (cut-off, 1.9 cm) and 87.9%, 0.865±0.072 (cut-off, 13 cm), respectively. In a subgroup without a fat component, only SUVmax was significantly different with an accuracy of 90.2% and AUC of 0.919±0.043. The optimal diagnostic flow by combining SUVmax and tumour size after dividing patients into two groups according to the presence of fat showed a sensitivity of 90.4%, a specificity of 95.5%, and an accuracy of 91.9%.
CONCLUSIONS: The combination of SUVmax and size according to the presence of a fat component may be the optimal PET/CT diagnostic criteria for distinguishing benign and malignant RPMs.
Copyright © 2018 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2019        PMID: 30638733     DOI: 10.1016/j.crad.2018.12.010

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  3 in total

1.  Factors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience.

Authors:  Filiz Cimen; Yetkin Agackiran; Sevim Düzgün; Melike Aloglu; Aysegül Senturk; Sükran Atikcan
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

2.  Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma.

Authors:  Jun Hyeok Lim; Joon Young Choi; Yunjoo Im; Hongseok Yoo; Byung Woo Jhun; Byeong-Ho Jeong; Hye Yun Park; Kyungjong Lee; Hojoong Kim; O Jung Kwon; Joungho Han; Myung-Ju Ahn; Jhingook Kim; Sang-Won Um
Journal:  PLoS One       Date:  2020-02-18       Impact factor: 3.240

3.  Automated procedure assessing the accuracy of HRCT-PET registration applied in functional virtual bronchoscopy.

Authors:  Gábor Opposits; Marianna Nagy; Zoltán Barta; Csaba Aranyi; Dániel Szabó; Attila Makai; Imre Varga; László Galuska; Lajos Trón; László Balkay; Miklós Emri
Journal:  EJNMMI Res       Date:  2021-07-26       Impact factor: 3.138

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.